Kirkwood F. Jr. Adams
#165,043
Most Influential Person Now
Kirkwood F. Jr. Adams's AcademicInfluence.com Rankings
Kirkwood F. Jr. Adamsmedical Degrees
Medical
#3381
World Rank
#3849
Historical Rank
Cardiology
#354
World Rank
#365
Historical Rank
Public Health
#529
World Rank
#546
Historical Rank
Epidemiology
#646
World Rank
#672
Historical Rank
Kirkwood F. Jr. Adamsphilosophy Degrees
Philosophy
#9677
World Rank
#13269
Historical Rank
Logic
#6646
World Rank
#8181
Historical Rank
Download Badge
Medical Philosophy
Kirkwood F. Jr. Adams's Degrees
- Doctorate Medicine University of California, San Francisco
- Masters Public Health University of California, Berkeley
Why Is Kirkwood F. Jr. Adams Influential?
(Suggest an Edit or Addition)Kirkwood F. Jr. Adams's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). (2005) (1974)
- Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. (2004) (1595)
- Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. (1996) (1327)
- Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. (2005) (1245)
- Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. (2002) (1096)
- Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (2005) (966)
- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial (2013) (834)
- State of the art: Using natriuretic peptide levels in clinical practice (2008) (780)
- Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. (1993) (750)
- Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. (2006) (723)
- In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). (2005) (704)
- A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). (1997) (650)
- Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial (2006) (601)
- Effect of nesiritide in patients with acute decompensated heart failure. (2011) (516)
- Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). (1999) (489)
- Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study (2005) (469)
- Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. (2013) (411)
- Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial (2007) (408)
- Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. (2004) (400)
- Consensus recommendations for the management of chronic heart failure: Introduction (1999) (391)
- Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. (2010) (370)
- Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. (2006) (362)
- Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial (2004) (345)
- Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial (2017) (343)
- Relationship of depression to death or hospitalization in patients with heart failure. (2007) (341)
- Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. (1999) (340)
- Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis (2005) (329)
- HFSA 2006 comprehensive heart failure practice guideline (2006) (329)
- Risk stratification after hospitalization for decompensated heart failure. (2004) (325)
- Relation between gender, etiology and survival in patients with symptomatic heart failure. (1996) (303)
- Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) (2008) (280)
- Gender differences in advanced heart failure: insights from the BEST study. (2003) (280)
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. (2020) (266)
- Anemia as a risk factor and therapeutic target in heart failure. (2004) (263)
- Gender differences in survival in advanced heart failure. Insights from the FIRST study. (1999) (261)
- Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. (2004) (257)
- Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. (2003) (238)
- Vasopressin: a new target for the treatment of heart failure. (2003) (214)
- Digoxin in the management of cardiovascular disorders. (2004) (209)
- The pathophysiology of acute heart failure--is it all about fluid accumulation? (2008) (203)
- Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial (2016) (200)
- The problem of decompensated heart failure: nomenclature, classification, and risk stratification. (2003) (199)
- The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure. (2009) (187)
- Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. (2005) (180)
- Clinical definition and epidemiology of advanced heart failure. (1998) (177)
- Production of arrhythmias by elevated carboxyhemoglobin in patients with coronary artery disease. (1990) (176)
- Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. (2001) (170)
- Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. (2017) (158)
- Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. (2007) (156)
- Clinical benefits of low serum digoxin concentrations in heart failure. (2002) (155)
- Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial (2007) (154)
- Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). (2003) (145)
- ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL (2004) (142)
- Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward (2010) (141)
- Effects of Serelaxin in Patients with Acute Heart Failure. (2019) (129)
- Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial (2007) (126)
- Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. (2011) (124)
- Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. (2014) (124)
- β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure (2005) (123)
- Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. (2014) (119)
- Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes (2013) (116)
- Beta-blocker use and outcomes among hospitalized heart failure patients. (2006) (102)
- Endorphins are related to pain perception in coronary artery disease. (1987) (102)
- Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization From Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial (2007) (99)
- Charting a roadmap for heart failure biomarker studies. (2014) (95)
- Acute elevation of blood carboxyhemoglobin to 6% impairs exercise performance and aggravates symptoms in patients with ischemic heart disease. (1988) (95)
- Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers (1998) (89)
- Effect of oral digoxin in high‐risk heart failure patients: a pre‐specified subgroup analysis of the DIG trial (2013) (85)
- HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. Heart Failure Society of America. (2000) (81)
- Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? (2003) (81)
- Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy (2007) (78)
- Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. (2017) (75)
- Cardiac Calcitropes, Myotropes, and Mitotropes: JACC Review Topic of the Week. (2019) (74)
- Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart Failure—Reply (2005) (73)
- Synergistic polymorphisms of &bgr;1 and &agr;2C-adrenergic receptors and the influence on left ventricular ejection fraction response to &bgr;-blocker therapy in heart failure (2007) (73)
- Oral Torsemide in Patients With Chronic Congestive Heart Failure: Effects on Body Weight, Edema, and Electrolyte Excretion (1994) (72)
- Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate‐lowering properties (2014) (71)
- Galectin-3: A Modifiable Risk Factor in Heart Failure (2014) (71)
- The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). (2005) (71)
- Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. (2004) (69)
- Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. (2003) (69)
- Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. (2016) (68)
- Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. (2007) (68)
- Safety and Efficacy of Epoprostenol in Patients with Severe Congestive Heart Failure (1995) (68)
- Outcomes by gender in the African-American Heart Failure Trial. (2006) (65)
- Effect of Acute Magnesium Administration on the Frequency of Ventricular Arrhythmia in Patients With Heart Failure (1994) (61)
- NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. (2019) (59)
- In‐hospital worsening heart failure (2015) (57)
- Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. (2007) (56)
- Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions (2014) (56)
- New epidemiologic perspectives concerning mild-to-moderate heart failure. (2001) (55)
- Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. (2009) (54)
- The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. (2014) (53)
- Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. (2020) (53)
- Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. (2009) (53)
- Acute heart failure associated with high admission blood pressure — A distinct vascular disorder? (2007) (53)
- Coping styles in heart failure patients with depressive symptoms. (2009) (53)
- Hormone replacement therapy is associated with improved survival in women with advanced heart failure. (2003) (51)
- Lack of effect of low levels of carboxyhemoglobin on cardiovascular function in patients with ischemic heart disease. (1987) (51)
- Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure (2002) (51)
- Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. (2000) (46)
- The influence of age and gender on left ventricular response to supine exercise in asymptomatic normal subjects. (1987) (46)
- Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial (2016) (44)
- Effect of Fluoxetine on Carvedilol Pharmacokinetics, CYP2D6 Activity, and Autonomic Balance in Heart Failure Patients (2001) (44)
- Heart failure as an endpoint in heart failure and non-heart failure cardiovascular clinical trials: the need for a consensus definition. (2008) (44)
- Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. (2003) (44)
- Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. (2009) (44)
- Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials (2020) (44)
- Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. (1998) (42)
- Surrogate End Points in Heart Failure (2002) (41)
- Association between adrenergic receptor genotypes and beta‐blocker dose in heart failure patients: analysis from the HF‐ACTION DNA substudy (2013) (41)
- B-type natriuretic peptide: from bench to bedside. (2003) (41)
- Effects of low-level carbon monoxide exposure on resting and exercise-induced ventricular arrhythmias in patients with coronary artery disease and no baseline ectopy. (1989) (40)
- The effect of copper on erythrocyte deformability: a possible mechanism of hemolysis in acute copper intoxication. (1979) (40)
- Association of body mass, gender and race with heart failure primarily due to hypertension. (1999) (39)
- Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. (2001) (38)
- Relationship of Clinical Signs and Chest-X Ray Congestion to the Efficacy of Digoxin in Patients with Chronic Heart Failure: A Retrospective Analysis of the Digoxin Investigation Group Trial (2006) (38)
- Patients with mild heart failure worsen during withdrawal from digoxin therapy. (1997) (38)
- Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. (2019) (37)
- Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long‐term prognosis? (2009) (37)
- Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. (2007) (37)
- Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators. (1993) (37)
- N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. (2009) (34)
- Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) (2013) (33)
- Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. (2014) (32)
- Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. (2018) (32)
- Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia (2008) (31)
- Effects of Coping Skills Training on Quality of Life, Disease Biomarkers, and Clinical Outcomes in Patients With Heart Failure: A Randomized Clinical Trial (2017) (31)
- Reactive hyperemia is associated with adverse clinical outcomes in heart failure. (2016) (30)
- Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). (2004) (30)
- Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure. (2007) (30)
- Review of Tolvaptan’s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions (2014) (29)
- HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction--pharmacological approaches. (2000) (28)
- Clinical predictors of in-hospital mortality in acutely decompensated heart failure-piecing together the outcome puzzle. (2008) (28)
- Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure. (2008) (28)
- Post hoc subgroup analysis and the truth of a clinical trial. (1998) (27)
- Relationship between systolic blood pressure, ventricular volume and ischemic pain perception in patients with angina pectoris: a potential role for baroreceptors. (1989) (27)
- Clinical factors related to morbidity and mortality in high‐risk heart failure patients: the GUIDE‐IT predictive model and risk score (2019) (26)
- Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. (2012) (25)
- Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. (2015) (24)
- Risk stratification for in-hospital mortality in heart failure using classification and regression tree (CART) methodology: analysis of 33,046 patients in the ADHERE registry (2003) (23)
- Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure. (1995) (23)
- A perspective on re‐evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile (2014) (23)
- Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. (1995) (22)
- Biomarker guided therapy for heart failure: focus on natriuretic peptides (2010) (22)
- Pathophysiology of Heart Failure: Changing Perceptions (1996) (22)
- Beta‐blocker therapy in advanced heart failure: clinical characteristics and long‐term outcomes (1999) (21)
- Surrogate end points in heart failure trials. (2003) (21)
- Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials (2015) (21)
- Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. (2018) (19)
- Systems biology and heart failure: concepts, methods, and potential research applications (2010) (19)
- Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. (2010) (19)
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). (2002) (18)
- Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. (2018) (17)
- Coping effectively with heart failure (COPE-HF): design and rationale of a telephone-based coping skills intervention. (2011) (17)
- Antiarrhythmic action of pharmacological administration of magnesium in heart failure: a critical review of new data. (1995) (17)
- Comparison of in-hospital mortality in patients treated with nesiritide vs. other parenteral vasoactive medications for acutely decompensated heart failure: an analysis from a large prospective registry database (2003) (17)
- Biomarker-guided therapies in heart failure: a forum for unified strategies. (2013) (17)
- Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease. (1998) (16)
- Aligning quality and payment for heart failure care: defining the challenges. (2003) (16)
- Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure (2017) (15)
- Endorphins and pain perception in silent myocardial ischemia. (1988) (15)
- Clinical predictors of worsening heart failure during withdrawal from digoxin therapy. (1998) (14)
- Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). (2019) (14)
- Interrelationships between left ventricular volume and output during exercise in healthy subjects. (1992) (14)
- Evolution of regional left ventricular wall motion abnormalities in acute Q and non-Q wave myocardial infarction. (1987) (14)
- Results of a twelve week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure (2003) (14)
- Survival rates are similar between African American and white patients with heart failure. (2003) (13)
- Which ?-blocker for heart failure? (2001) (12)
- Effects of 4 percent and 6 percent carboxyhemoglobin on arrhythmia production in patients with coronary artery disease. (1991) (12)
- Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III (2010) (12)
- Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure (2015) (11)
- Fiolan International Randomized Survival Trial (FIRST): Final results (1996) (11)
- Propranolol therapy alters estimation of potential cardiovascular risk derived from submaximal postinfarction exercise testing. (1991) (11)
- Translating heart failure guidelines into clinical practice: Clinical science and the art of medicine (2001) (11)
- 788-2 Six Minute Walk Test Gives Prognostic Information in Severe Hear Failure (1995) (10)
- The COMET trial. (2005) (10)
- STAMINA-HFP (study of anemia in a heart failure population) registry: rationale, design, and patient characteristics (2003) (9)
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). (2002) (9)
- Rapid Clinical Assessment of Patients with Acute Heart Failure: First Blood Pressure and Oxygen Saturation – Is That All We Need? (2009) (9)
- Is there a role for epoprostenol in the management of heart failure? (1995) (9)
- Positive treadmill stress tests post myocardial infarction in patients with single-vessel coronary disease. (1985) (9)
- Torsemide: a pyridine-sulfonylurea loop diuretic. (1995) (9)
- RANDOMIZED INTRAVENOUS TEZOSENTAN STUDY-4 INVESTIGATORS TEZOSENTAN IN PATIENTS WITH ACUTE HEART FAILURE AND ACUTE CORONARY SYNDROMES (2003) (9)
- Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). (2003) (9)
- Erythrocyte filterability and lysosomal enzymes in patients requiring cardiopulmonary bypass. (1975) (8)
- Perspective on the clinical application of troponin in heart failure and states of cardiac injury (2010) (8)
- b1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to b-blocker therapy (2005) (8)
- The AHCPR Clinical Practice Guideline for Heart Failure Revisited (1997) (8)
- Natriuretic peptides for the treatment of acute heart failure: a focus on nesiritide in recent clinical trials (2015) (7)
- 842-5 Anemia is common in patients with heart failure seen in specialty and community cardiology clinics: Results from the STAMINA: HFP registry (study of anemia in a heart failure population) (2004) (7)
- Relative bioavailability of tolvaptan administered via nasogastric tube and tolvaptan tablets swallowed intact. (2013) (7)
- Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure (2020) (7)
- Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge (2017) (7)
- Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment. (2002) (6)
- Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients. (2014) (6)
- Clinical practice guidelines for heart failure. (1998) (6)
- BETA-1 ADRENERGIC RECEPTOR GENOTYPE SER49GLY IS ASSOCIATED WITH BETA-BLOCKER SURVIVAL BENEFIT IN PATIENTS WITH HEART FAILURE (2012) (5)
- Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies). (2022) (5)
- 1069-119 Predictors of mortality in patients hospitalized with worsening heart failure: Insights from the ACTIV in CHF trial (2004) (5)
- Utility of natriuretic peptide testing in the evaluation and management of acute decompensated heart failure (2010) (5)
- Dose Response of &bgr;-Blockers in Adrenergic Receptor Polymorphism Genotypes (2018) (4)
- Current Perspectives on β‐Receptor Antagonists in the Treatment of Symptomatic Ventricular Dysfunction (1996) (4)
- How should COMET influence heart failure practice? (2004) (4)
- Which beta-blocker for heart failure? (2001) (4)
- Developing Clinical Practice Guidelines for Heart Failure: Creative Process and Practice Implications (2000) (4)
- Gender differences in survival in patients with advanced heart failure. (1996) (4)
- Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. (2003) (4)
- Guiding heart failure care by invasive hemodynamic measurements: possible or useful? (2002) (4)
- Family History of Dilated Cardiomyopathy among Patients with Heart Failure from the HF‐ACTION Genetic Ancillary Study (2013) (4)
- Tezosentan in patients with acuteheart failure and acute coronary syndromes (2003) (4)
- Comparison of coronary angiography and early oral dipyridamole thallium-201 scintigraphy in patients receiving thrombolytic therapy for acute myocardial infarction. (1990) (4)
- Pathophysiology of Heart Failure (1993) (3)
- Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice (2023) (3)
- ARG389GLY beta‐1 adrenergic receptor polymorphism and left ventricular remodeling changes to beta‐blocker therapy (2004) (3)
- Lower Hemoglobin Is Associated with Persistently Reduced Quality of Life in Unselected Patients with Heart Failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (2004) (3)
- Managing acute decompensated heart failure (2005) (3)
- 114 Anemia as a predictor of death and rehospitalization in patients with advanced decompensated heart failure: insights from the OPTIME‐CHF study (2003) (3)
- Effects of erythromycin or rifampin on steady state losartan pharmacokinetics in healthy volunteers (1997) (3)
- Metoprolol Reverses Left Ventricular Remodeling in Patients with Asymptomatic Systolic Dysfunction: The REVERT Trial (2005) (3)
- Cardiac Calcitropes, Myotropes, andMitotropes (3)
- Beta-blockers in heart failure: how far have we progressed? (2002) (2)
- Introduction: biomarkers in heart failure (2010) (2)
- Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction (2021) (2)
- Favorable effects of digoxin on mortality and morbidity in patients with class IV congestive heart failure due to systolic dysfunction: Retrospective analysis of the DIG study (2003) (2)
- 842-6 Anemia is associated with reduced health status measures in patients with heart failure: Results from the STAMINA: HFP (study of anemia in a heart failure population) registry (2004) (2)
- Effect of Natriuretic Peptide-Guided Therapy on Outcomes in High-Risk Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial (2017) (2)
- Gheorghiade et al Digoxin in the Management of CV Disorders (2004) (2)
- Erythrocyte filterability in the burned patient (1979) (2)
- Gender differences in heart failure clinical characteristics and therapy: Report from UNITE-HF Multicenter Heart Failure Database (2001) (2)
- Abstract 17649: Elevated Galectin-3 Levels and Prediction of Mode of Death in Heart Failure: Insights from the HF-ACTION Study (2012) (2)
- Investigating the Role of Thiazide-Like Diuretics in Acute Heart Failure: Potential Approach to an Unmet Need. (2016) (2)
- Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B‐type natriuretic peptide level: insights from the GALACTIC‐HF trial (2023) (2)
- The influence of comorbidities on achieving an N‐terminal pro‐b‐type natriuretic peptide target: a secondary analysis of the GUIDE‐IT trial (2021) (2)
- Understanding the Management of Heart Failure (2000) (1)
- Anemia in acute and chronic heart failure (2005) (1)
- Scientific Basis of Hyponatremia and Its Clinical Presentations (2011) (1)
- Chapter 40 – Development and Implementation of Practice Guidelines in Heart Failure (2011) (1)
- PILOT STUDY OF THE RELATIONSHIP OF AMBIENT COPEPTIN TO THE AQUARETIC EFFECTS OF TOLVAPTAN IN PATIENTS WITH HEART FAILURE (2015) (1)
- Acute heart failure: nomenclature, pathophysiology, and outcome measures (2005) (1)
- Effect of fluoxetine on carvedilol stereo‐specific pharmacokinetics in patients with heart failure (1999) (1)
- Abstract 15360: Biomarker-Guided Heart Failure Therapy Results in Significant Reverse Left Ventricular Remodeling Among Patients Achieving NT-proBNP Goal: Insights From the GUIDE-IT Trial (2017) (1)
- Risk of death in patients with preserved systolic function: retrospective analysis of the digitalis investigational group (DIG) trial (2003) (1)
- ELDERLY PATIENTS ARE LESS LIKELY TO RECEIVE EVIDENCE-BASED MEDICATIONS INDICATED FOR SYSTOLIC HEART FAILURE: RESULTS FROM THE STUDY OF ANEMIA IN A HEART FAILURE POPULATION (STAMINA-HFP) REGISTRY (2010) (1)
- Circulating Angiokines are Associated with Reverse Remodeling and Outcomes in Chronic Heart Failure. (2023) (1)
- Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches (2020) (1)
- Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF. (2023) (1)
- Changes in Resting and Maximal Exercise Heart Rate during Dosing of Beta Blocker Therapy in Patients with Systolic Heart Failure (2008) (1)
- Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial. (2003) (1)
- Women with preserved systolic function have better survival than men: retrospective analysis of the digitalis investigational group (DIG) trial (2004) (1)
- Prognosis determination in heart failure. Discussion (2001) (1)
- Relationship of Left Ventricular Size to Long-Term Outcome Varies with Degree of Clinical Heart Failure: Results from the UNC Heart Failure Database (2008) (0)
- Continuing Education Information (2011) (0)
- PHARMACOGENOMIC ANALYSES IN ASCEND-HF INDICATE INFLUENCE OF NPR3ON NESIRITIDE BLOOD PRESSURE EFFECT (2021) (0)
- Abstract 10790: Association of Beta Blocker Dose with Outcome in Heart Failure is Not Altered by Age: Insights from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (2010) (0)
- Do hemodynamics always predict survival in advanced heart failure? A second look at FIRST (2000) (0)
- Immune System Alterations in Acute Heart Failure (2008) (0)
- Rationale and Design of the GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study (2014) (0)
- Clinical severity predicts response to digoxin: a retrospective analysis of the digitalis investigational group (DIG) trial (2004) (0)
- The management of decompensated heart failure resulting in hospitalization: Proceedings from an expert meeting to review current concepts and to define future directions - Introduction (2003) (0)
- Contemporary aspects of intravenous vasodilator therapy with nesiritide or nitrates in acute heart failure (2005) (0)
- Lower hemoglobin is associated with reduced survival in unselected patients with heart failure: results from the study of anemia in a heart failure population (STAMINA-HFP) registry (2004) (0)
- Abstract 17332: A Multi-Marker Approach for Risk Stratification in Patients With Chronic Heart Failure: Insights From the HF-ACTION Trial (2017) (0)
- Influence of Neurohormonal Antagonists on the Association of Loop Diuretic Dose with Mortality in Patients with Heart Failure: Insights From the UNITE-HF Registry (2016) (0)
- Pathophysioloyg of heart failure (1993) (0)
- Hyponatremia in Acute Heart Failure – A Marker of Hyperglycemia and Reduced Renal Perfusion? (2006) (0)
- ADRENERGIC RECEPTOR POLYMORPHISMS INTERACT WITH BETA-BLOCKER DOSE EFFECT ON HEART FAILURE OUTCOMES ESPECIALLY IN BLACK RACE: RESULTS FROM HF-ACTION DNA SUBSTUDY (2015) (0)
- CO-MORBIDITIES AND ETHNICITY/RACE PREDICT MORBIDITY AND MORTALITY IN HIGH RISK HEART FAILURE PATIENTS WITH SYSTOLIC DYSFUNCTION: THE GUIDE-IT PREDICTIVE RISK MODEL (2018) (0)
- N-terminal Pro-Brain Natriuretic Peptide and Exercise Capacity in Chronic Heart Failure: Data from the HF-ACTION Study (2013) (0)
- Thanks to Reviewers2002 (2002) (0)
- 694 Diabetes reduces the likelihood of more favorable outcomes in women than men with heart failure: Retrospective analysis of the DIG trial (2006) (0)
- Subject Index Vol. 116, 2010 (2010) (0)
- RELATIONSHIP BETWEEN EXERCISE TRAINING AND CHANGES IN BIOMARKERS OF MYOCARDIAL STRESS, INJURY AND INFLAMMATION IN PATIENTS WITH CHRONIC HEART FAILURE (2013) (0)
- Troponin Increase in Acute Heart Failure – A Marker of Ischemia, a Measure of Severity or Both? (2006) (0)
- Contents Vol. 116, 2010 (2010) (0)
- Influence of calcium administration on the short-term hemodynamic and anti-ischemic effects of nifedipine. (1991) (0)
- Pathophysiology of the spectrum of acute heart failure: de novo heart failure, decompensated heart failure, and advanced refractory heart failure (2005) (0)
- USE OF HYDRALAZINE/NITRATE, ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR AND OTHER GUIDELINE-DIRECTED MEDICAL THERAPIES AMONGST AFRICAN AMERICANS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION: INSIGHTS FROM CHAMP-HF (2019) (0)
- The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-Controlled Trial in Acute Heart Failure (2016) (0)
- Blood filtration in patients with peripheral vascular disease (2016) (0)
- Propranolol Therapy Alters Risk Markers During Post-Infarction Treadmill Testing (1988) (0)
- Influence of etiology on the survival advantage of women with advanced heart failure (2003) (0)
- Acute Heart Failure Associated with High Admission Blood Pressure – A Very Common, yet Distinct Vascular Disorder? (2006) (0)
- Earlier Onset of Ischemia After Exposure to Low Level Carbon Monoxide in Patients With Ischemic Heart Disease (1987) (0)
- Abstract 16114: Incremental Prognostic Utility by Cost and Complexity in Chronic Heart Failure (2013) (0)
- Relationship between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis from the HF- ACTION Study (2014) (0)
- 1012-126 Contemporary dosing of angiotensin converting enzyme inhibitors and beta blockers in chronic heart failure: Report from the STAMINA:HFP (study of anemia in a heart failure population) registry (2004) (0)
- Abstract 12023: Relationship of Beta-Blocker (BB) Dose with Outcomes in Ambulatory Heart Failure (HF) Patients with Systolic Dysfunction: Results from the HF-ACTION Trial (2011) (0)
- Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing (1990) (0)
- HEALTH RELATED QUALITY OF LIFE AND FUNCTIONAL CLASS ARE INDEPENDENTLY RELATED TO OUTCOMES IN UNSELECTED OUTPATIENTS WITH HEART FAILURE: INSIGHTS FROM THE STUDY OF ANEMIA IN A HEART FAILURE POPULATION (STAMINA-HFP) REGISTRY (2010) (0)
- Impaired renal function is common in outpatients with heart failure: results from the STAMINA-HFP (study of anemia in a heart failure population) registry (2003) (0)
- Diabetes Reduces the Likelihood of More Favorable Outcomes in Women Than Men with Heart Failure: Retrospective Analysis of the DIG Trial (2006) (0)
- Renal function, independent of ejection fraction and heart size, is a predictor of mortality in patients with heart failure and preserved ejection fraction: a retrospective analysis of the digitalis investigational group (DIG) trial (2004) (0)
- Strength in Numbers: A Team-Based Approach to Managing Patients with Hyponatremia. (2018) (0)
- JAMA Peer Reviewers in 2018. (2019) (0)
- HFSA 2006 Comprehensive Heart Failure Practice Guideline HFSA 2006 Comprehensive Heart Failure Practice Guideline (2006) (0)
- The impact of gender on prognosis in patients with advanced heart failure (2002) (0)
- Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. (2022) (0)
- POPULATION-SPECIFIC GENETIC VARIATIONS INCREASE HAZARD OF MORTALITY OR REHOSPITALIZATION IN HEART FAILURE PATIENTS (2018) (0)
- Rationale and Design for the UNC Duke Acute Decompensated Heart Failure with Hypertension Study (UNDU ADHF-HTN) (2007) (0)
- ALPHA-2C ADRENERGIC RECEPTOR POLYMORPHISM INTERACTS WITH BETA-BLOCKER DOSE EFFECT ON HEART FAILURE OUTCOMES DIFFERENTLY IN BLACK RACE: RESULTS FROM THE HF-ACTION DNA SUBSTUDY (2015) (0)
- INTERACTION BETWEEN ST2 LEVELS AND EXERCISE TRAINING IN PATIENTS WITH CHRONIC HEART FAILURE: ANALYSIS FROM THE HF-ACTION TRIAL (2012) (0)
- Focus on cilazapril: An angiotensin converting enzyme inhibitor for the treatment of hypertension (1991) (0)
- INFLUENCE OF LOW VERSUS HIGH DOSE ON THE ASSOCIATION OF LOOP DIURECTIC AND MORTALITY IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM THE UNITE-HF REGISTRY (2017) (0)
- ACUTE MYOCARDIAL INFARCTION AND PROLONGED CARDIAC ARREST: A COMPLEX PATIENT CASE STUDY (2017) (0)
- The effect of varying exercise protocols on LV ejection fraction (1996) (0)
- Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure (2002) (0)
- A prospective randomized study of nesiritide versus dobutamine in decompensated heart failure (PRESERVD-HF): design and preliminary data (2003) (0)
- Digoxin in the Management of Cardiovascular Disorders PDATE (2004) (0)
- Are angiotensin-converting enzyme inhibitors and β-blockers making an impact on the epidemiology of heart failure? (2004) (0)
- Beta-blocker therapy after myocardial infarction: secondary prevention in all patients? (1985) (0)
- Journal of Cardiac Failure: Editorial comment (1999) (0)
- Clinical profile of the acute heart failure patient (2005) (0)
- Short-term prognosis in females with no or insignificant coronary disease and an diagnostic exercise test (1990) (0)
- Evidence for an Association of Beta Blocker Dose with Outcome in Heart Failure: Insights from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (2010) (0)
- Decreasing Hemoglobin during Follow-Up Is Associated with Declining Quality of Life in Unselected Outpatients with Heart Failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry (2006) (0)
- Optimal Medical Therapy in Heart Failure: Reasons for Lack of Medication Titration in the GUIDE IT Trial (2019) (0)
- Effect of beta‐1 adrenergic receptor polymorphisms on the tolerability of metoprolol CR/XL in heart failure (2004) (0)
- Case Studies in Hypervolemic Hyponatremia (2011) (0)
- &bgr;1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to &bgr;-blocker therapy (2005) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kirkwood F. Jr. Adams?
Kirkwood F. Jr. Adams is affiliated with the following schools:
